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Aim To assess the effects of protein C activator (PCA) from 
Agkistrodon halys snake venom on cardiac fibrosis in strep-
tozotocin (STZ) induced diabetic rat model, and investi-
gate the mechanisms of its action.
Methods PCA was identified by one-dimensional reversed 
phase liquid chromatography – mass spectrometry/mass 
spectrometry. Male Sprague-Dawley rats (120-140 g) were 
randomly assigned to negative control (NC) and diabetic 
group. Diabetes was induced by STZ in high-fat diet fed 
rats. Diabetic group was subdivided into three groups: dia-
betic group (DM), diabetic group treated with PCA (0.5, 2, 
and 8 mg/kg), and diabetic group treated with metformin 
(5 mg/kg, positive control). NC and DM groups received 
the same volume of distilled water. Left ventricular mass 
index (LVWI) and collagen volume fraction were measured 
by hematoxylin and eosin and Masson staining. Transform-
ing growth factor beta-1 (TGF-β1) and interleukin 1 beta 
(IL-1β) levels were determined by enzyme-linked immuno-
sorbent assay.
Results The diabetic rat model was successfully estab-
lished by STZ induction and high-fat diet. Glucose level, 
LVWI, TGF-β1 and IL-1β level, and collagen volume fraction 
were significantly reduced in diabetic rats treated by PCA 
in a dose-dependent manner (P < 0.050), especially in the 
high dose (8 mg/kg) group (P < 0.010), compared to dia-
betes group. The high dose PCA had the same effect as 
metformin positive control in reducing the level of fasting 
blood glucose. PCA decreased the expression of MMP-2 
and reduced that of TIMP-2.
Conclusion Our results indicate that PCA has anti-fibrotic 
effects and that it may be used to treat myocardial fibrosis.
Received: June 7, 2015
Accepted: October 25, 2015
Correspondence to:  
Liuwang Nie 
The Provincial Key Lab of the 
Conservation and Exploitation 
Research of Biological Resources in 
Anhui 
Life Science College, Anhui Normal 
University 
Beijing East Road 1#, Wuhu 241000 
People’s Republic of China  
lwnie@ahnu.edu.cn
Shu Li1,2, Yun Hong3, Xin 
Jin4, Genbao Zhang2, 
Zaichang Hu5, Liuwang 
Nie1
1Life Science College, Anhui Normal 
University, Wuhu, China
2Department of Pathophysiology, 
Wannan Medical College, Wuhu, 
China
3Department of Ultrasonography, 
Yijishan Hospital, Wuhu, China
4Department of Pharmacology, 
Wannan Medical College, Wuhu, 
China
5Department of Clinic Medicine, 
Wannan Medical College, Wuhu, 
China
The first two authors contributed 
equally to the study.
A new Agkistrodon halys 
venom-purified protein C 
activator prevents myocardial 
fibrosis in diabetic rats
BASIC SCIENCE 
 
Croat Med J. 2015;56:439-46 
doi: 10.3325/cmj.2015.56.439
BASIC SCIENCE440 Croat Med J. 2015;56:439-46
www.cmj.hr
The main complications and leading causes of death 
among patients with diabetes mellitus are coronary artery 
disease (CAD), hypertension, and diabetic cardiomyopathy 
(DCM), a direct adverse effect of diabetes on the heart (1). 
Epidemiological data showed that the risk for heart failure 
is respectively 2.4-fold and 5-fold higher in diabetic men 
and women than in non-diabetic individuals (2). Indeed, 
diabetes is a significant risk factor for heart failure and an 
independent risk factor for increased mortality among 
individuals with heart failure (3). Myocardial fibrosis (MF) 
plays a major role in the pathophysiology of DCM (4). It is 
also strongly associated with some angiocardiopathy dis-
eases such as hypertension, DCM, rheumatic heart disease, 
and myocardial infarction (5,6).
Fibrosis is a complex process characterized by cardiac fi-
broblast accumulation and excess extracellular matrix de-
position of collagen I and III (7), which is a leading cause of 
diabetes and heart failure. Therefore, in diabetes and many 
cardiovascular diseases, it is vital to develop appropriate 
drugs to prevent MF. Angiotensin-converting enzyme in-
hibitors (ACEI) have been shown in animal models to pre-
vent and treat MF in early stage; clinically, ACEI improve 
ventricular remodeling and the prognosis of heart failure 
(8). However, they cause adverse reactions such as cough, 
hypotension, and nausea, and increase the treatment 
costs, which all indicates the need for novel candidates in 
MF treatment.
Snake venom contains multiple proteins and peptides 
with different structure and function (9), and is an ex-
tremely rich source of pharmacologically active mole-
cules with a considerable clinical and medical potential 
(10-14). Many toxins are being explored and developed 
for treatment of hypertension, thrombosis, and cancer. In 
recent years, special attention has been paid to proteins 
affecting hemostasis, in order to design new therapeu-
tic agents for blood coagulation and other hematologi-
cal disorders (15). Protein C activators (PCA) are proteas-
es that activate protein C in the mammalian coagulation 
system in vitro. PCA activity was first reported in venom 
extracts of the snake Agkistrodon contortrix contortrix in 
1985 (16). The reptilian PCA has attracted increasing at-
tention in both clinical and basic research (17). Other 
functions of snake venom PCA have to be further studied. 
Therefore, we hypothesized that snake venom PCA could 
protect against cardiac fibrosis in DCM. We established 
a type 2 diabetes model to investigate the cardio-pro-
tective properties of PCA in DCM and determine the 
underlying mechanisms of its action.
MateriaLS aNd MetHodS
PCa purification and liquid chromatography – mass 
spectrometry/mass spectrometry
The isolation and purification of PCA were carried out 
as previously described (15). Briefly, DEAE-Cellulose, CM-
Sephadex C-50, and SP-Sephadex G-75 (GE, Pittsburgh, PA, 
USA) column chromatography were used to purify PCA 
from Agkistrodon halys venom. Kaolin partial thrombo-
plastin time, prothrombin time of normal rabbit plasma, 
and color producing reaction ability (determined by chro-
mogenic substrate assay) were used to assess the antico-
agulant activity of PCA-containing fractions. The respec-
tive kits were purchased from SUNBIO Co., Ltd (Shanghai, 
China). The purified PCA was digested by trypsin and ana-
lyzed by one-dimensional reversed phase liquid chroma-
tography – mass spectrometry/mass spectrometry (1D 
LC-MS/MS, Thermo Fisher Scientific, Waltham, MA, USA) at 
the Research Center for Life Sciences, University of Science 
and Technology of China in 2012.
experiments design
Male Sprague-Dawley (SD) rats (120-140 g) were ob-
tained from the Nanjing Qinlong Shan Animal Experi-
mental Center. They were housed at 22°C under a 12-h 
light-dark cycle. All experimental procedures were ap-
proved by the Animal Care Committee of Wannan Medi-
cal College. After one week of adaptation, the animals 
were randomly assigned to negative control (NC, n = 8) 
and diabetic (n = 50) group. Control animals received 
normal chow, and the diabetic group animals were fed 
a high-fat diet (34.5% fat, 17.5% protein, 48% carbohy-
drate; HFK Bio-Technology, Beijing, China). Four weeks 
later, rats were intraperitoneally injected with a single 
dose of streptozotocin (STZ) (Sigma, St. Louis, MO, USA) 
at 30 mg/kg dissolved in 0.1 mol/L citrate buffer (pH 
4.5) (18). Negative control rats were intraperitoneally in-
jected with citrate buffer alone. One week after STZ in-
jection, rats with fasting blood glucose (FBG) levels ex-
ceeding 11.1 mmol/L in two consecutive analyses were 
considered to be diabetic. Diabetic rats were subdivided 
into three groups: diabetes group (DM, n = 8), diabetes 
group treated by gavage with PC (0.5, 2, and 8 mg/kg, 
n = 24), and diabetes group treated by metformin (5 mg/
kg, positive control, n = 8). NC and DM groups received 
the same volume of distilled water. Ten weeks after the 
first drug gavage, rats were sacrificed, and the hearts 
were excised and weighed.
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tissue preparation
The heart was excised from the chest and weighted after 
trimming of large vessels. A left ventricular (LV) section was 
cut off transversely at the mid-ventricular level and fixed in 
paraformaldehyde (4%). Histological paraffin-embedded 
sections (5 μm) were prepared for histology staining. The 
remaining portion of the LV tissue was snap frozen and 
stored at -80°C for Western blot analysis.
Hematoxylin and eosin (He) and Masson staining
Left ventricular tissues were fixed in 4% neutral formal-
dehyde, paraffin-embedded, and sliced to 5-μm sections. 
The sections were stained with HE and Masson’s trichrome 
staining (measure of fibrosis). Collagen volume fraction 
(CVF) was analyzed with the Image-Pro Plus 5.0 analysis 
software (Media Cybernetics, Rockville, MD, USA). Perivas-
cular collagen was excluded from the CVF assessment.
enzyme-linked immunosorbent assay (eLiSa)
Blood samples were centrifuged at 1000 × g for 15 min at 
4°C, and plasma samples were immediately stored at -70°C 
until use. Plasma transforming growth factor beta-1 (TGF-
β1) and interleukin 1 beta (IL-1β) levels were measured with 
commercially available ELISA kits (Jiancheng Bioengineering 
Institute, Nanjing, China) according to the manufacturer’s in-
structions. Each sample was analyzed in duplicate.
rNa isolation and quantitative real-time polymerase 
chain reaction (qrt-PCr)
Total RNA was isolated from heart tissue samples using 
TRIzol reagent (Invitrogen, Waltham, MA, USA). Reverse 
transcription (RT) was performed with the RT reagent kit 
(Takara Biotechnology Co., Ltd, Dalian, China); qRT PCR 
(qRT-PCR) was carried out with SYBR Premix Ex TaqII (Ta-
kara Biotechnology). All reactions were performed accord-
ing to the manufacturer’s protocols. The following primers 
were used: matrix metallopeptidase (MMP)-2 (Forward, 5’- 
CGATGTCTCCCCCAAAACAG -3’; Reverse, 5’- GCATGGTCTC-
GATGGTGTTC -3’); β-actin (Forward, 5’-CTGCACCACCAACT-
GCTTAG-3’; Reverse, 5’-AGGTCCACCACTGACACGTT-3’); 
tissue inhibitor of metalloproteases (TIMP) (Forward, 5’-
TCCCCAGAAATCATCGAGAC-3’; Reverse, 5’-ATGGCTGAA-
CAGGGAAACAC-3’). Amplification was carried out on an 
ABI prism 7300 Real-Time PCR system (Applied Biosystems, 
Carlsbad, USA). Data were analyzed by the ΔΔCt method 
(19), with β-actin as an internal control.
Western blotting
Protein extraction from LV tissues was performed using RIPA 
buffer (20). A total of 40 μg protein from each sample was 
separated by 10% SDS-polyacrylamide gel electrophoresis, 
and electrophoretically transferred to polyvinylidene fluo-
ride membranes. The membranes were blocked with 5% 
skimmed milk for 1 h, and incubated with specific primary 
antibodies, including anti-MMP2 (Abcam, Cambridge, UK. 
1:2000), anti-TIMP2 (Abcam, 1:1000), and anti-β-actin (Sig-
ma, St. Louis, MO, USA 1:5000) antibodies overnight at 4°C. 
After incubation with horseradish peroxidase-conjugated 
secondary antibodies (Abcam) for 2 h, chemiluminescent 
signals were detected with the EasySee Western Blot Kit 
(Biyuntian, Hangzhou, China). Band intensity was analyzed 
using the Adobe Photoshop 7.0.1 software (Adobe Sys-
tems Incorporated, San Jose, CA, USA) and compared with 
the internal standard β-actin.
Statistical analysis
Experimental data are presented as mean ± standard de-
viation (SD), since all the values were normally distribut-
ed. All statistical analyses were performed using one way 
analysis of variance (ANOVA) and t test for independent 
samples. P < 0.050 was considered statistically significant. 
Statistical analysis was performed using SPSS v. 19.0 (IBM 
Corp, Armonk, NY, USA).
reSuLtS
PCa identification
The mass spectrum of the Agkistrodon halys venom puri-
fied PCA was compared with Agkistrodon halys database 
in NCBI using the SEQUEST algorithm (21) (Supplementary 
Table 1). Interestingly, this PCA has not been previously re-
ported, but showed 90.27% similarity with acurhagin pre-
cursor (Deinagkistrodon acutus) (22). These results suggest 
that PCA is a new metalloproteinase.
Glucose level, body weight, and left ventricular weight 
of rats
The STZ induced diabetic rats displayed yellow fur, poly-
dipsia, polyuria, and reduced body weight. Interestingly, 
PCA affected these symptoms in a dose dependent man-
ner. Diabetic rats had significantly higher glucose level 
and left ventricular mass index (LVWI) than negative 
controls (P = 0.003) (23). However, glucose level and 
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LVWI in diabetic rats were reduced after treatment with 
PCA in a dose dependent manner. PCA treatment with 0.5, 
2, and 8 mg/kg reduced LVWI to 3.13 ± 0.17, 2.77 ± 0.21, 
and 2.22 ± 0.23, respectively, and FBG levels to 16.53 ± 1.79, 
13.88 ± 1.17, and 10.26 ± 1.09 mmol/L, respectively. In posi-
tive control group, LVWI and FBG were also reduced to 
2.08 ± 0.19 and 9.37 ± 1.30 mmol/L, respectively. Of note, 
FBG and LVWI were still higher in the PCA groups than in 
negative controls. Taken together, these data suggested 
that the model of diabetes in rats was successfully estab-
lished, and diabetes symptoms were alleviated by PCA (Ta-
ble 1).
effects of PCa on plasma tGF-β1 and iL-1β levels
In diabetic rats, circulating TGF-β1 (102.29 ± 16.46 vs 
65.98 ± 10.88 pg/mL) and IL-1β (126.08 ± 25.03 vs 82.84 ± 12.34 
pg/mL) were higher than in negative control group (P = 0.001). 
However, treatment with middle (2 mg/kg) and high doses 
(8 mg/kg) of PCA significantly decreased the levels of TGF-β1 
(12.23 ± 1.37 and 9.77 ± 1.23 pg/mL) and IL-1β (157.65 ± 10.43 
and 124.44 ± 9.86 pg/mL), respectively (P = 0.031 vs diabetic 
group for both). These results indicate that PCA suppressed 
the expression of TGF-β1 and IL-1β (Table 2).
tabLe 1. Left ventricular mass index (LVWi) and fasting blood 
glucose (FbG) in negative control group (NC), diabetic group 
(dM), diabetic groups treated with different doses of protein 
C activator (PCa), and positive control diabetic group treated 







NC (n = 8) 1.98 ± 0.13  4.93 ± 0.20
DM (n = 8) 3.57 ± 0.24* 20.11 ± 2.61*
DM+ 0.5 mg/kg PCA (n = 8) 3.13 ± 0.17† 16.53 ± 1.79†
DM+ 2 mg/kg PCA (n = 8) 2.77 ± 0.21† 13.88 ± 1.17†
DM+ 8 mg/kg PCA (n = 8) 2.22 ± 0.23‡ 10.26 ± 1.09‡
PC (n = 8) 2.08 ± 0.19‡  9.37 ± 1.30‡
*P < 0.001 compared with NC group.
†P < 0.009 compared with dM group.
‡P < 0.001 compared with dM group.
tabLe 2. Levels of transforming growth factor beta-1 (tGF-β1) 
and interleukin 1 beta (iL-1β) in in negative control group (NC), 
diabetic group (dM), diabetic groups treated with different 
doses of protein C activator (PCa), and positive control diabetic 
group treated with metformin (PC). all values are given as 
mean ± standard deviation
Group tGF-β1 (pg/mL) iL-1β (pg/mL)
NC (n = 8)  5.63 ± 0.67  97.46 ± 7.48
DM (n = 8) 17.33 ± 2.06* 213.79 ± 13.66*
DM+ 0.5 mg/kg PCA (n = 8) 14.19 ± 1.86† 170.41 ± 12.97†
DM+ 2 mg/kg PCA (n = 8) 12.23 ± 1.37† 157.65 ± 10.43†
DM+ 8 mg/kg PCA (n = 8)  9.77 ± 1.23‡ 124.44 ± 9.86‡
PC (n = 8) 10.31 ± 0.87‡ 134.26 ± 1.17‡
#P < 0.004 compared with NC group.
†P < 0.003 compared with dM group.
‡P < 0.001 compared with dM group.
FiGure 1. effect of protein C activator (PCa) on cardiac morphology hematoxylin and eosin staining of sections. (A) negative control 
group (n = 8); (B) diabetes model group (n = 8); (C) diabetic rats treated with PCa at 0.5 mg/kg (n = 8); (D) diabetic rats treated with 
PCa at 2 mg/kg (n = 8); (E) diabetic rats treated with PCa at 8 mg/kg (n = 8). Magnification: ×200.
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effects of PCa on cardiac fibrosis
The effects of PCA on cardiac injury were examined after 
HE staining. The cardiomyocytes in the negative control 
group were well-organized, while in DM animals they were 
disorganized. PCA treatment ameliorated myocyte disor-
ganization (Figure 1). The degree of myocardial fibrosis was 
assessed by Masson’s trichrome staining (Figure 2). Posi-
tively stained fibrotic areas (collagen staining in blue color) 
were evaluated under a microscope. DM group showed a 
diffuse, reticular, pockety, and disorganized collagen net-
work. A significant increase in the degree of fibrosis was 
found in DM rats as compared with negative control ani-
mals (P < 0.001). However, PCA markedly attenuated these 
pathological changes (Figure 2). As compared with neg-
ative controls, CVF was significantly increased in diabet-
ic rats (Figure 2F). However, in this group PCA treatment 
overtly decreased CVF values in a dose dependent man-
FiGure 2. effect of protein C activator (PCa) on cardiac fibrosis Masson’s trichrome staining: (A) negative control group (n = 8); (B) 
diabetes model group (n = 8); (C) diabetic rats treated with PCa at 0.5 mg/kg (n = 8); (D) diabetic rats treated with PCa at 2 mg/kg 
(n = 8); (E) diabetic rats treated with PCa at 8 mg/kg (n = 8). Positive stained fibrotic areas appear blue. Magnification: ×200.
FiGure 3. effect of protein C activator (PCa) on mrNa expression of matrix metallopeptidase-2 and tissue inhibitor of metallopro-
teases-2. data are presented as mean ± standard deviation (n = 8); *P < 0.050 and **P < 0.010 compared with negative control group; 
#P < 0.050 and ##P < 0.010 compared with diabetes mellitus group.
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ner. These results suggested that PCA inhibited the cardiac 
expression of collagen.
effect of PCa on MMP-2 and tiMP-2 mrNa and protein 
expression levels
Real-time quantitative PCR and Western blotting were used 
to assess the expression of MMP-2 and TIMP-2. MMP-2 
mRNA and protein levels were significantly higher in the di-
abetes group than in negative controls (P < 0.001, Figure 3 
and 4); meanwhile, gene and protein TIMP-2 expression was 
also higher in diabetes group. PCA dramatically ameliorated 
these changes. These results indicated that PCA decreased 
the expression of MMP-2 and reduced that of TIMP-2.
diSCuSSioN
In this research, we provided the first evidence that PCA 
has the potential to attenuate myocardial fibrosis and de-
crease inflammatory reaction in STZ induced diabetic rats. 
Based on the obtained results, further investigations were 
performed by focusing on the potential mechanisms in-
volved. The results indicated that PCA (0.5, 2, and 8 mg/kg) 
treatment significantly reduced inflammatory lesions, de-
creased inflammatory cytokine expression, and reduced 
collagen content and MMP-2 expression. The results sug-
gested that inhibition of myocardial inflammation acti-
vation and pro-fibrogenic factor production might be 
critical mechanism of anti-fibrogenic action of PCA in 
diabetic rats.
In order to investigate the effects of PCA on myocardial fi-
brosis in diabetic rats, high-fat diet and intraperitoneal in-
jection of STZ (30 mg/kg) were used to establish a diabe-
tes model. Consistent with previous findings (24), diabetic 
rats had elevated LVWI, glucose, and myocardial injury, in-
dicating that HF diet and STZ treatment cause significant 
pathological cardiac remodeling (25). On the other hand, 
Masson’s trichrome staining indicated a significant in-
crease in the degree of left ventricle myocardial fibrosis in 
the DM group compared with negative controls (26). How-
ever, treatment with PCA (2 and 8 mg/kg) significantly de-
creased blood glucose level, myocardial fibrosis, and CVF, 
and these changes were associated with lesion ameliora-
tion. Further studies should be carried out to understand 
the regulatory mechanism of PCA in inducing the blood 
glucose level in type 2 diabetic rats. We speculated that 
PCA could stabilize the use of glucose in the peripheral tis-
sues and therefore have an indirect hypoglycemic effect.
Since the inflammation activation plays an important role in 
cardiac remodeling (27), we assessed whether PCA effects 
on fibrosis were associated with a modulation of circulating 
pro-inflammatory cytokine levels. TGF-β1 and IL-1β levels in 
diabetic rats were found to be elevated, suggesting a sus-
tained inflammation activated by STZ (30 mg/kg) and high-
fat diet. Interestingly, PCA treatment obviously decreased 
the levels of both cytokines. TGF-β1 was shown to trigger in-
flammatory signaling pathways causing concentric left ven-
tricular hypertrophy and increasing collagen deposition and 
myocardial fibrosis (28,29). IL-1β was directly correlated with 
FiGure 4. effects of protein C activator (PCa) on protein expression of metallopeptidase-2 and tissue inhibitor of metalloproteas-
es-2. data are presented as mean ± standard deviation (n = 8); *P < 0.050 and **P < 0.010 compared with the negative control group; 
#P < 0.050 and ##P < 0.010 compared with diabetes mellitus group.
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inflammatory reaction, and caused myocardial collagen and 
cardiomyocyte apoptosis (30,31). Favorable regulatory ef-
fects of PCA on TGF-β1 and IL-1β levels suggest that inhibi-
tion of these two cytokines might be a key mechanism of 
PCA anti-fibrotic effects in diabetic rats.
MMPs belong to the family of structurally related zinc con-
taining endopeptidases, which play pivotal roles in inflam-
matory diseases, including oxidative stress-associated car-
diac fibrosis (32). Importantly, increased levels of MMP-2 
have been observed in coronary blood samples from pa-
tients with myocardial infarction (33). In this study, PCA de-
creased MMP-2 levels in diabetic rats, suggesting that this 
protein might control the MMPs balance.
TIMP-2 as endogenous inhibitor plays an important role 
in the MMP-2 regulation, especially in the development 
of cardiac dysfunction and myocardial interstitial fibrosis 
(34). Under normal physiological conditions, MMP-2 forms 
a non-active complex with its inhibitors, the TIMP proteins. 
Once the level of cytokines (eg, TGF-β1 and IL-1β) increas-
es, the balance of MMPs and TIMPs is altered with the de-
composition of the MMP-TIMP complex. The increase in 
the activity of MMPs and TIMPs is followed by an increase 
in the degree of myocardial fibrosis in diabetic rats (35). Our 
results indicate that PCA not only decreased MMP-2 levels 
but also sustained the MMP-TIMP balance in the diabetic 
rat myocardium. These data might partly explain the inhi-
bition of PCA against progressive cardiac dysfunction and 
myocardial interstitial fibrosis. A limitation of the study may 
be the diabetic model used, since there are other, more 
up-to-date type 2 diabetes models, but for the purposes of 
this study, such models were not of utmost importance.
In conclusion, PCA has potential anti-fibrotic effects, like 
modulating the balance between inflammatory cytokine 
levels and collagen content, as well as modulating MMP 
expression and sustaining the MMP-TIMP balance. These 
findings indicate that PCA administration could attenu-
ate STZ-induced cardiac fibrosis in diabetic rats and have 
therapeutic potential against myocardial injury induced by 
high-fat diet and intraperitoneal STZ administration.
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